2型向治疗对呼吸道感染风险的影响
Kathryn Smiley1,2, Nora Zuhdi3, Bob Geng1,2,4
1Department of Allergy and Immunology, Rady Children's Hospital-San Diego.
Current opinion in allergy and clinical immunology
|December 8, 2025
概括
对过敏性疾病的2型 (T2) 细胞因子疗法恢复了上皮屏障和免疫平衡,维持或降低了呼吸道感染风险. 这些治疗提供了治疗和免疫再平衡的双重好处.
科学领域:
- 免疫学 免疫学 免疫学
- 过敏学 过敏学
- 呼吸系统医学 呼吸系统医学
背景情况:
- 2型 (T2) 炎症是由IL-4,IL-13,IL-5和IgE等细胞因子驱动的,会损害上皮质完整性和粘膜防御,增加呼吸道感染的易感性.
- 过敏性疾病的特征是T2驱动的炎症,破坏呼吸道的自然防御.
研究的目的:
- 审查T2细胞因子向治疗对过敏患者呼吸道感染风险的影响.
- 检查这些疗法如何恢复上皮质屏障功能并重新平衡免疫反应.
主要方法:
- 在过敏性疾病中对T2细胞因子向生物制剂 (如dupilumab,tralokinumab,omalizumab) 的研究的文献综述.
- 对临床试验数据的分析和专项分析后的分析,重点关注呼吸道感染率和上皮屏障标志物.
主要成果:
- 针对T2通路 (IL-4,IL-13,IL-5,IgE) 的生物药物恢复了上皮质的完整性,并促进了Th1/Th17的抗菌活性.
- 杜皮卢马布证明了呼吸道感染的减少;IL-13抑制剂支持粘膜平衡;IL-5抑制剂对感染风险的影响最小;奥马利祖马布增强了抗病毒途径.
- 这些疗法共同改善表皮屏障功能,调节免疫反应,从而更好地控制感染.
结论:
- 调节T2的生物制剂通过控制过敏炎症和恢复表皮和免疫平衡,提供了双重益处.
- 这些疗法有助于维持或减少过敏疾病患者的呼吸道感染风险.
- 需要进一步的研究来评估长期感染结果,特别是在高风险人群中.
更多相关视频
08:42Isolating Bronchial Epithelial Cells from Resected Lung Tissue for Biobanking and Establishing Well-Differentiated Air-Liquid Interface Cultures
Published on: May 26, 2023
3.9K
16:56Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
Published on: August 30, 2014
17.5K
相关概念视频
01:17Drugs Used in Lower Respiratory Disorders: Overview
1.0K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.0K
01:29Acute Respiratory Failure-V
425
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
425
01:25Transmission-based Precautions II: Airborne and Protective Environment
1.8K
Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
1.8K
01:30Pneumonia I: Introduction
702
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
702
01:19Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K
01:28Pneumonia IV: Management
731
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
731